Skip to content
  • Home
  • Company
    • About Us
    • Leadership
    • Management
    • Board of Directors
    • Scientific
      Advisory Board
  • Science
    • Evorpacept
    • Publications
  • Pipeline
    • Clinical Trials
    • Expanded
      Access Policy
  • Careers
    • Current Jobs
  • Investors
    • Overview
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financials & Filings
    • IR Resources
  • Contact

ALTA-002, a SIRPα-Directed TLR9 Agonist Antibody Conjugate, Activates Myeloid Cells and Promotes Anti-Tumor Immunity

Post navigation

Previous: Evorpacept (ALX148), a CD47 Myeloid Checkpoint Inhibitor, in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) and with Gastric/Gastroesophageal Cancer (GC); ASPEN-01
Next: A Phase 2 Study of Evorpacept (ALX148) in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (HNSCC); ASPEN-03
TOP
  • Home
  • Company
    • About Us
    • Leadership
    • Management
    • Board of Directors
    • Scientific
      Advisory Board
  • Science
    • Evorpacept
    • Publications
  • Pipeline
    • Clinical Trials
    • Expanded
      Access Policy
  • Careers
    • Current Jobs
  • Investors
    • Overview
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financials & Filings
    • IR Resources
  • Contact
© ALX Oncology Inc., All rights reserved.
Privacy Policy Twitter LinkedIn